- Home
- BTCT vs GDTC Comparison
BTCT vs GDTC Comparison
Compare BTCT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTCT
- GDTC
- Stock Information
- Founded
- BTCT 2006
- GDTC 2018
- Country
- BTCT Singapore
- GDTC Singapore
- Employees
- BTCT N/A
- GDTC N/A
- Industry
- BTCT Other Consumer Services
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- BTCT Real Estate
- GDTC Health Care
- Exchange
- BTCT Nasdaq
- GDTC Nasdaq
- Market Cap
- BTCT 24.5M
- GDTC 28.0M
- IPO Year
- BTCT N/A
- GDTC 2023
- Fundamental
- Price
- BTCT $3.22
- GDTC $2.02
- Analyst Decision
- BTCT
- GDTC Buy
- Analyst Count
- BTCT 0
- GDTC 1
- Target Price
- BTCT N/A
- GDTC $5.00
- AVG Volume (30 Days)
- BTCT 369.6K
- GDTC 9.2K
- Earning Date
- BTCT 06-17-2025
- GDTC 01-01-0001
- Dividend Yield
- BTCT N/A
- GDTC N/A
- EPS Growth
- BTCT N/A
- GDTC N/A
- EPS
- BTCT N/A
- GDTC N/A
- Revenue
- BTCT $11,675,000.00
- GDTC $368,838.00
- Revenue This Year
- BTCT $13.58
- GDTC $5.37
- Revenue Next Year
- BTCT N/A
- GDTC N/A
- P/E Ratio
- BTCT N/A
- GDTC N/A
- Revenue Growth
- BTCT 28.68
- GDTC N/A
- 52 Week Low
- BTCT $1.32
- GDTC $1.20
- 52 Week High
- BTCT $26.58
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- BTCT 33.81
- GDTC 38.29
- Support Level
- BTCT $3.23
- GDTC $2.00
- Resistance Level
- BTCT $3.42
- GDTC $2.45
- Average True Range (ATR)
- BTCT 0.25
- GDTC 0.13
- MACD
- BTCT -0.07
- GDTC -0.02
- Stochastic Oscillator
- BTCT 6.45
- GDTC 4.46
About BTCT BTC Digital Ltd.
BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.